American Journal of Cardiovascular Drugs

, Volume 3, Issue 4, pp 241–244

Could Influenza Vaccination Prevent Myocardial Infarction, Stroke and Sudden Cardiac Death?

Leading Article


Acute myocardial infarction (AMI), sudden cardiac death and atherothrombotic stroke, which share a common pathogenesis involving disrupted atherosclerotic plaque and intravascular thrombosis, vary seasonally, with peak incidence in winter months. This seasonality is similar to that of upper respiratory infections, of which 38% are due to influenza. Infections such as influenza produce many biochemical, cellular, and hemostatic changes that could predispose to plaque disruption and thrombosis. Infections, particularly of the respiratory tract, often precede AMI and stroke. Four observational studies and one small clinical trial suggest that influenza vaccination can reduce the occurrence of sudden death, AMI, and stroke by approximately 50%. Influenza vaccine is very well-tolerated. With up to 16% of adults contracting influenza each year and the vaccine reducing the incidence of influenza by 50%, influenza vaccination could make a substantial public health impact on acute cardiac and neurovascular events.


  1. 1.
    American Heart Association. 2002 Heart and stroke statistical update. Dallas (TX): American Heart Association, 2001Google Scholar
  2. 2.
    Siscovick DS, Raghunathan TE, Lin D, et al. Influenza vaccination and the risk of primary cardiac arrest. Am J Epidemiol 2000; 152: 674–7PubMedCrossRefGoogle Scholar
  3. 3.
    Naghavi M, Barlas Z, Saidaty S, et al. Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation 2000; 102: 3039–45PubMedCrossRefGoogle Scholar
  4. 4.
    Nichol JL, Nordin J, Heckbert SR, et al. Influenza vaccination and reduction of hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 2003; 348: 1322–32PubMedCrossRefGoogle Scholar
  5. 5.
    Lavallee P, Perchaud V, Gautier-Bertrand M, et al. Association between influenza vaccination and reduced risk of brain infarction. Stroke 2002; 33: 513–8PubMedCrossRefGoogle Scholar
  6. 6.
    Gurfinkle EP, Leon de la Fuente R, Mendiz O, et al. Influenza vaccine pilot study in acute coronary syndromes and planned percutaneous coronary interventions: The FLU Vaccination Acute Coronary Syndromes (FLUVACS) study. Circulation 2002; 105: 2143–7CrossRefGoogle Scholar
  7. 7.
    Libby P. Changing concepts of atherosclerosis. J Intern Med 2000; 247: 349–58PubMedCrossRefGoogle Scholar
  8. 8.
    Shah PK. Plaque disruption and thrombosis. Cardiol Clin 1999; 17: 271–81PubMedCrossRefGoogle Scholar
  9. 9.
    Zaman AG, Helft G, Worthley SG, et al. The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis 2000; 149: 251–66PubMedCrossRefGoogle Scholar
  10. 10.
    Spencer FA, Goldberg RJ, Becker RC, et al. Seasonal distribution of acute myocardial infarction in the second national registry of myocardial infarction. J Am Coll Cardiol 1998; 31: 1226–33PubMedCrossRefGoogle Scholar
  11. 11.
    Sheth T, Nair C, Muller J, et al. Increased winter mortality from acute myocardial infarction and stroke: the effect of age. J Am Coll Cardiol 1999; 33: 1916–9PubMedCrossRefGoogle Scholar
  12. 12.
    Jakovljevic D, Salomaa V, Sivenius J, et al. Seasonal variation in the occurrence of stroke in the Finnish adult population: The FINMONICA Stroke Register. Stroke 1996; 27: 1774–9PubMedCrossRefGoogle Scholar
  13. 13.
    Ku CS, Yang CY, Chiang HT, et al. Absence of seasonal variation in myocardial infarction onset in a region without temperature extremes. Cardiology 1998; 89: 277–82PubMedCrossRefGoogle Scholar
  14. 14.
    Monto AS, Sullivan KM. Acute respiratory illness in the community: frequency of illness and the agents involved. Epidemiol Infect 1993; 110: 145–60PubMedCrossRefGoogle Scholar
  15. 15.
    Monto AS, Koopman JS, Bryan ER. The Tecumseh study of illness: XIV. occurrence of respiratory viruses, 1976–1981. Am J Epidemiol 1986; 124: 359–67PubMedGoogle Scholar
  16. 16.
    Kawahara J, Sano H, Fukuzaki H, et al. Acute effects of exposure to cold on blood pressure, platelet function, and sympathetic nervous activity in humans. Am J Hypertens 1989; 2: 724–6PubMedGoogle Scholar
  17. 17.
    Gordon DJ, Hydes J, Trost DC, et al. Cyclic seasonal variation in plasma lipid and lipoprotein levels: the Lipid Research Clinics Coronary Primary Prevention Trial Placebo Control Group. J Clin Epidemiol 1988; 41: 679–89PubMedCrossRefGoogle Scholar
  18. 18.
    Bull GM, Brozovic M, Chakrabarti R, et al. Relationship of air temperature to various chemical, haematologic, and haemostatic variables. J Clin Pathol 1979; 32: 16–20PubMedCrossRefGoogle Scholar
  19. 19.
    Bussfeld D, Bacher M, Moritz A, et al. Expression of transcription factor genes after influenza A virus infection. Immunobiology 1997; 198: 291–8PubMedCrossRefGoogle Scholar
  20. 20.
    Morrow DA, Ridker PM. C-reactive protein, inflammation, and coronary risk. Med Clin North Am 2000; 84: 149–61PubMedCrossRefGoogle Scholar
  21. 21.
    Woodhouse PR, Khaw KT, Plummer M, et al. Seasonal variations of plasma fibrinogen and factor VII activity in the elderly: winter infections and deaths from cardiovascular disease. Lancet 1994; 343: 435–9PubMedCrossRefGoogle Scholar
  22. 22.
    Gronholdt MLM, Dalager-Pederen S, Falk E. Coronary atherosclerosis: determinants of plaque rupture. Eur Heart J 1998; 19 Suppl. C: C24–9PubMedGoogle Scholar
  23. 23.
    Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657–71PubMedCrossRefGoogle Scholar
  24. 24.
    Visser MR, Tracy PB, Vercellotti GM, et al. Enhanced thrombin generation and platelet binding on herpes simplex virus-infected endothelium. Proc Natl Acad Sci USA 1988; 85: 8227–30PubMedCrossRefGoogle Scholar
  25. 25.
    Etingin OR, Silverstein RL, Hajjar DP. Von Willebrand factor mediates platelet adhesion to virally infected endothelial cells. Proc Natl Acad Sci USA 1992; 90: 5153–6CrossRefGoogle Scholar
  26. 26.
    Key NS, Vercellotti GM, Winklemann JC, et al. Infection of vascular endothelial cells with herpes simplex virus enhances tissue factor activity and reduces thrombomodulin expression. Proc Natl Acad Sci U S A 1990; 87: 7095–9PubMedCrossRefGoogle Scholar
  27. 27.
    van Dam-Mieras MCE, Muller AD, van Hinsbergh VWM, et al. The procoagulant response of cytomegalovirus infected endothelial cells. Thromb Haemost 1992; 68: 364–70PubMedGoogle Scholar
  28. 28.
    Van Lenten BJ, Wagner AC, Navab M, et al. Acute influenza A infection promotes increased macrophage infiltration into the artery wall that is prevented by apolipoprotein A-1. Circulation 2001; 104 Suppl. II: II–97Google Scholar
  29. 29.
    Osier W. Diseases of the arteries. In: Osier W, editor. Modern medicine: its practice and theory. Philadelphia (PA): Lea & Febiger, 1908: 429–47Google Scholar
  30. 30.
    Gordon T, Thorn T. The recent decrease in CHD mortality. Prev Med 1975; 4: 115–25PubMedCrossRefGoogle Scholar
  31. 31.
    Pesonen E, Siitonen O. Acute myocardial infarction precipitated by infectious disease. Am Heart J 1981; 101: 512–3PubMedCrossRefGoogle Scholar
  32. 32.
    Spodick DH, Flessas AP, Johnson MM. Association of acute respiratory symptoms with onset of acute myocardial infarction: prospective investigation of 150 consecutive patients and matched control patients. Am J Cardiol 1984; 53: 481–2PubMedCrossRefGoogle Scholar
  33. 33.
    Jick H, Vasilakis C, Derby LE. Antihypertensive drugs and fatal myocardial infarction in persons with uncomplicated essential hypertension. Epidemiology 1997; 8: 446–8PubMedCrossRefGoogle Scholar
  34. 34.
    Zheng ZJ, Mittleman MA, Tolfer GH, et al. Infections prior to acute myocardial infarction onset [abstract]. J Am Coll Cardiol 1998; 31 Suppl. A: 132ACrossRefGoogle Scholar
  35. 35.
    Pettinen J, Valonen P. The risk of myocardial infarction among Finnish farmers seeking medical care for an infection. Am J Public Health 1996; 86: 1440–2CrossRefGoogle Scholar
  36. 36.
    Gillum RF, Jacobs Jr DR, Luepker RV, et al. Cardiovascular mortality trends in Minnesota, 1960–1978: the Minnesota Heart Survey. J Chronic Dis 1984; 37: 301–9PubMedCrossRefGoogle Scholar
  37. 37.
    Jackson LA, Yu O, Heckbert SR, et al. Influenza vaccination is not associated with a reduction in recurrent coronary events. Am J Epidemiol 2002; 156: 634–40PubMedCrossRefGoogle Scholar
  38. 38.
    Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997; 350: 430–6PubMedCrossRefGoogle Scholar
  39. 39.
    Minick CR, Fabricant CG, Fabricant J, et al. Atherosclerosis induced by infection with herpesvirus. Am J Pathol 1979; 96: 673–706PubMedGoogle Scholar
  40. 40.
    Epstein SE. The multiple mechanisms by which infection may contribute to atherosclerosis development and course. Circ Res 2002; 91: 2–4CrossRefGoogle Scholar
  41. 41.
    Gross PA, Hermogenes AW, Sacks HS, et al. The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature. Ann Intern Med 1995; 123: 518–27PubMedGoogle Scholar
  42. 42.
    Govaert TM, Thijs CT, Masurel N, et al. The efficacy of influenza vaccination in elderly individuals: a randomized double-blind placebo-controlled trial. JAMA 1994; 272: 1661–5PubMedCrossRefGoogle Scholar
  43. 43.
    Roacelli JD, Bass JW, Pang L. Guillain-Barre syndrome and influenza vaccination in the US Army, 1980–1988. Am J Epidemiol 1991; 133: 952–5Google Scholar
  44. 44.
    Kasky T, Terracciano GL, Magder L, et al. The Guillian-Barre syndrome and the 1992–1993 and 1993–1994 influenza vaccines. N Engl J Med 1998; 339: 1797–802CrossRefGoogle Scholar
  45. 45.
    Nichol KL, Margolis KL, Lind A, et al. Side effects associated with influenza vaccination in healthy working adults. Arch Intern Med 1996; 156: 1546–50PubMedCrossRefGoogle Scholar
  46. 46.
    Govaert TME, Dinant GJ, Aretz K, et al. Adverse reactions to influenza vaccine in elderly people: randomized double blind placebo controlled trial. BMJ 1996; 307: 988–90CrossRefGoogle Scholar
  47. 47.
    Centers for Disease Control and Prevention. Influenza and pneumococcal vaccination levels among persons aged > 65 years: United States, 1999. MMWR Morb Mortal Wkly Rep 2001; 50: 532–7Google Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  1. 1.Division of Cardiovascular Diseases, Departments of Internal Medicine and Preventive MedicineUniversity of Kansas School of MedicineKansas CityUSA

Personalised recommendations